RTP Mobile Logo

Saturday, March 28, 2020, Toronto, Canada, 12:15 PM – 1:45 PM

Data + Perspectives: Clinical Investigators Explore the Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Update regarding COVID-19

The Society of Gynecologic Oncology (SGO) has announced it will not conduct its 2020 Annual Meeting on Women’s Cancer, March 28-31, in Toronto, Ontario, Canada. SGO is exploring alternatives for delivering the scientific and educational sessions, so please check back here for more updates on our satellite symposia. For up-to-date information on Research To Practice’s live events, please sign up for our email alerts.

Last updated 3/9/2020

Event Details

Metro Toronto Convention Centre
222 Bremner Blvd
Toronto, ON M5V 3L9

11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:45 PM — Educational Meeting

Meeting Room
Room 718 (Level 700 – South Building)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Michael J Birrer, MD, PhD
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
University of Arkansas
Little Rock, Arkansas

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David M O'Malley, MD
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and the James
Cancer Center
Columbus, Ohio

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Neil Love, MD
Research To Practice
Miami, Florida


This CME symposium will focus on the current and future role of immune checkpoint inhibitors and other novel therapies in the management of ovarian, cervical, and endometrial cancer. Research To Practice (RTP) president and medical oncologist Dr Neil Love will moderate the program, and 4 clinical investigators will serve as the faculty. Leading up to the event, each faculty member will be provide RTP with a number of interesting cases from their practice of patients with each disease for whom treatment with an approved or investigational agent was considered and/or administered. The activity will be divided into 4 modules, each featuring a blend of moderated case and panel discussion and a faculty member-led review of related scientific data and ongoing research. To make the program more interactive and relevant to those in the room, clinician attendees will use networked iPads® to complete a premeeting survey centered on the cases and topics to be presented. Survey results will be interspersed throughout the discussions within each module to foster additional debate among the panelists and ensure a variety of perspectives emerge. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will intersperse select inquiries throughout the discussions to foster additional conversation and ensure that a variety of perspectives emerge. A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Describe the biologic rationale for, published research data with, and ongoing evaluation of the use of immune checkpoint inhibitors in the management of ovarian (OC), endometrial (EC) and cervical cancer (CC), and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
  • Appraise the clinical research findings supporting the FDA approval of anti-PD-1 monotherapy for patients with PD-L1-positive, progressive metastatic CC, and counsel appropriate patients about the potential risks and benefits of this treatment approach.
  • Recall available data with the use of anti-PD-1/PD-L1 antibodies for patients with advanced EC either alone or in combination with other targeted agents and appreciate ongoing research efforts attempting to define the role of these agents in this disease.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of immune checkpoint inhibitors and other novel systemic therapies for the management of OC, CC and EC to support quality of life and continuation of therapy.
  • Review the mechanisms of action of, emerging efficacy data with and toxicity profiles of novel targeted agents under investigation in OC, CC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Eisai Inc, Merck, Seattle Genetics and Tesaro, A GSK Company.


Metro Toronto Convention Centre
222 Bremner Blvd
Toronto, ON M5V 3L9

Meeting Room
Room 718 (Level 700 – South Building)

The Metro Toronto Convention Centre is the main venue for the SGO Annual Meeting on Women’s Cancer.


This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.